Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Modeling and Similitude01:12

Modeling and Similitude

270
Scaled modeling is a fundamental technique in engineering, enabling the study of large and complex systems by creating smaller, manageable replicas that recreate critical characteristics of the original. In hydrology and civil infrastructure, for example, scaled models of dams help analyze water flow, turbulence, and pressure. This method allows for accurate predictions of real-world behavior within a controlled environment, significantly reducing the cost and time involved in full-scale...
270
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

74
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
74
Multicompartment Models: Overview01:14

Multicompartment Models: Overview

151
Multicompartment models are mathematical constructs that depict how drugs are distributed and eliminated within the body. They segment the body into several compartments, symbolizing various physiological or anatomical areas connected through drug transfer processes such as absorption, metabolism, distribution, and elimination.
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
151
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

107
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
107
Compartment Models: Single-Compartment Model01:14

Compartment Models: Single-Compartment Model

2.3K
The single-compartment model serves as a simplified representation of the human body. This model assumes that the body functions as a single, well-mixed open compartment. When a drug is administered intravenously, it enters the body and quickly distributes uniformly. The drug then undergoes biotransformation and elimination, ultimately leaving the body. The volume of this compartment is referred to as the apparent volume of distribution into which the drug can uniformly distribute. In this...
2.3K
Three-Compartment Open Model01:06

Three-Compartment Open Model

241
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
241

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A novel hollow-fiber infection model (HFIM) for antiviral PK/PD studies of CMV infection.

Antimicrobial agents and chemotherapy·2026
Same author

Activity of a three-phage combination against <i>Mycobacterium tuberculosis</i> in disease-relevant conditions.

bioRxiv : the preprint server for biology·2026
Same author

Copulas for Covariate Simulation in Pharmacometrics.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Assessing the impact of bacterial heterogeneity on bacteriophage population dynamics.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Semi-Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety.

Nature reviews. Drug discovery·2025
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
查看所有相关文章

相关实验视频

Updated: Jul 11, 2025

Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training
05:04

Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training

Published on: August 9, 2024

958

虚拟患者模拟使用模拟.

Laura B Zwep1, Tingjie Guo1, Thomas Nagler2

  • 1Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

Clinical pharmacology and therapeutics
|November 10, 2023
PubMed
概括
此摘要是机器生成的。

科普拉通过准确建模共变量关系来增强虚拟患者模拟,改善临床试验设计和剂量策略. 这种方法克服了当前技术的局限性,使得更现实的患者队列生成成为可能.

更多相关视频

Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations
12:09

Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations

Published on: January 8, 2013

13.7K
Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training
09:15

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training

Published on: February 10, 2022

3.5K

相关实验视频

Last Updated: Jul 11, 2025

Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training
05:04

Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training

Published on: August 9, 2024

958
Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations
12:09

Patient-specific Modeling of the Heart: Estimation of Ventricular Fiber Orientations

Published on: January 8, 2013

13.7K
Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training
09:15

Creation of Patient-Specific Silicone Cardiac Models with Applications in Pre-surgical Plans and Hands-on Training

Published on: February 10, 2022

3.5K

科学领域:

  • 制药指标 (Pharmacometrics) 是一个指标.
  • 计算生物学 计算生物学
  • 统计建模 统计建模

背景情况:

  • 虚拟患者模拟对于基于模型的临床试验设计和个性化的剂量至关重要.
  • 目前的模拟方法难以准确地表示患者共变量之间的相关性.
  • 数据共享的局限性往往限制了对现实世界的个人患者数据的访问.

研究的目的:

  • 在虚拟患者模拟中引入和评估模拟患者相关的共变量.
  • 解决当前共变量模拟方法的局限性,以基于模型的剂量和试验优化.
  • 通过保持协变依赖来提高虚拟患者队伍的现实性.

主要方法:

  • 使用copula,一种多变量分布函数,以建模共变量集合的联合分布.
  • 对比了基于的模拟策略与替代方法的性能.
  • 在几个案例研究中应用了copulas,以证明它们在虚拟患者模拟中的实用性.

主要成果:

  • 科普拉斯成功地复制了现实的患者特征,包括个体共变量及其依赖结构.
  • 基于的模拟超越了替代方法,特别是在高维的共变量集合中.
  • 证明了 copulas 能够保留多个共同变量之间的复杂关系的能力.

结论:

  • 科普拉为虚拟患者模拟提供了一种多功能和可通用的方法.
  • 这种方法有效地保留了共变量之间的关系,增强了模拟现实性.
  • 科普拉斯促进了开放科学战略,促进了患者数据集的再利用.